About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

FDA Approves 'Five-day-after' Contraceptive Pill

by VR Sreeraman on August 14, 2010 at 1:31 PM
Font : A-A+

 FDA Approves 'Five-day-after' Contraceptive Pill

A US regulatory agency on Friday approved an emergency contraceptive pill that can prevent pregnancy if taken up to five days after unprotected sex.

The Food and Drug Administration said it granted approval for the drug, called ella, after two phase III clinical trials that "provided compelling data on efficacy and sufficient information on safety."

Advertisement

The drug, manufactured by French firm HRA Pharma, successfully "prevents pregnancy when taken orally within 120 hours (five days) after a contraceptive failure or unprotected intercourse," the FDA said in a statement.

"It is not intended for routine use as a contraceptive," the agency added.

The drug works by inhibiting or delaying ovulation, and has side effects similar to other emergency contraceptives already on the market, such as Plan B, which prevents pregnancy if taken within 72 hours after intercourse.

The drug's approval followed a positive recommendation by an FDA advisory committee on June 17.

The drug has been available in Europe since May 2009, under the name ellaOne, and will be distributed into the United States by New Jersey-based Watson Pharma Inc.

Source: AFP
Advertisement
Advertisement
Advertisement

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

FDA Approves 'Five-day-after' Contraceptive Pill Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests